For over 30 years, Ted Schroeder has been involved in the sales, marketing, and development of antibiotics, and he currently serves as the CEO of Nabriva Therapeutics. He joins the podcast today to discuss the current work being done at Nabriva, which involves the development of a new class of IV antibiotics for the treatment of community-acquired pneumonia in adults—the first of its kind in the US in over two decades.

 The second product Nabriva is working on has been around for nearly four decades but has never been available in the US, and it’s been shown to be effective in tackling complicated urinary tract infections and multidrug-resistant strains of bacteria. These antibiotics could limit or altogether eliminate the need for hospital stays for many people. To learn more about the work being done, tune in.

You’ll discover the details of all this and more, including:

• What makes gram negative bacterial infections so much more difficult to treat than gram-positive bacterial infections
• How strong the clinical-based evidence is for the effectiveness of these antibiotics
• What’s on the horizon in the near future for Nabriva Therapeutics, pharmacology, and anti-infective agents

For more information, visit https://www.nabriva.com/.

Podcast: Play in new window | Download | Embed